Oruka Therapeutics ORKA
$95.81 −$1.76 (-1.80%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $95.81 0.00%
Open$95.86
Prev close$97.57
Day range$93.30 – $97.24
Volume1.98M
Market cap$6.50B
P/E (TTM)–
Dividend yield–
ORKA Stock News
Headlines matching Oruka Therapeutics or the ORKA ticker, most recent first.
- LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $175
- H.C. Wainwright Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $120
- Wedbush Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $165
- A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $120 to $175
- Barclays Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $160
- UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Fractyl Health, Inc. (GUTS) and Oruka Therapeutics (ORKA)
- TD Cowen Maintains Oruka Therapeutics(ORKA.US) With Buy Rating
- Piper Sandler Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $180
- A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $133 to $180
- A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $151 to $200
- LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $125
- Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), Alto Neuroscience, Inc. (ANRO) and Astrana Health (ASTH)
- UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $130 Positive
- Stifel Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $150
No comments yet — be the first to weigh in on ORKA.
Sign in to join the discussion.